Recommendations for the design of therapeutic trials for neonatal seizures

for the International Neonatal Consortium

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Although seizures have a higher incidence in neonates than any other age group and are associated with significant mortality and neurodevelopmental disability, treatment is largely guided by physician preference and tradition, due to a lack of data from well-designed clinical trials. There is increasing interest in conducting trials of novel drugs to treat neonatal seizures, but the unique characteristics of this disorder and patient population require special consideration with regard to trial design. The Critical Path Institute formed a global working group of experts and key stakeholders from academia, the pharmaceutical industry, regulatory agencies, neonatal nurse associations, and patient advocacy groups to develop consensus recommendations for design of clinical trials to treat neonatal seizures. The broad expertise and perspectives of this group were invaluable in developing recommendations addressing: (1) use of neonate-specific adaptive trial designs, (2) inclusion/exclusion criteria, (3) stratification and randomization, (4) statistical analysis, (5) safety monitoring, and (6) definitions of important outcomes. The guidelines are based on available literature and expert consensus, pharmacokinetic analyses, ethical considerations, and parental concerns. These recommendations will ultimately facilitate development of a Master Protocol and design of efficient and successful drug trials to improve the treatment and outcome for this highly vulnerable population.

Original languageEnglish (US)
JournalPediatric Research
DOIs
StatePublished - Jan 1 2018

Fingerprint

Seizures
Ethical Analysis
Clinical Trials
Newborn Infant
Patient Advocacy
Critical Pathways
Drug Industry
Vulnerable Populations
Random Allocation
Pharmaceutical Preparations
Therapeutics
Pharmacokinetics
Age Groups
Guidelines
Physicians
Safety
Mortality
Incidence
Population
Neonatal Nurses

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Recommendations for the design of therapeutic trials for neonatal seizures. / for the International Neonatal Consortium.

In: Pediatric Research, 01.01.2018.

Research output: Contribution to journalReview article

@article{0d6985b6f8744702872712512fc41c96,
title = "Recommendations for the design of therapeutic trials for neonatal seizures",
abstract = "Although seizures have a higher incidence in neonates than any other age group and are associated with significant mortality and neurodevelopmental disability, treatment is largely guided by physician preference and tradition, due to a lack of data from well-designed clinical trials. There is increasing interest in conducting trials of novel drugs to treat neonatal seizures, but the unique characteristics of this disorder and patient population require special consideration with regard to trial design. The Critical Path Institute formed a global working group of experts and key stakeholders from academia, the pharmaceutical industry, regulatory agencies, neonatal nurse associations, and patient advocacy groups to develop consensus recommendations for design of clinical trials to treat neonatal seizures. The broad expertise and perspectives of this group were invaluable in developing recommendations addressing: (1) use of neonate-specific adaptive trial designs, (2) inclusion/exclusion criteria, (3) stratification and randomization, (4) statistical analysis, (5) safety monitoring, and (6) definitions of important outcomes. The guidelines are based on available literature and expert consensus, pharmacokinetic analyses, ethical considerations, and parental concerns. These recommendations will ultimately facilitate development of a Master Protocol and design of efficient and successful drug trials to improve the treatment and outcome for this highly vulnerable population.",
author = "{for the International Neonatal Consortium} and Soul, {Janet S.} and Ronit Pressler and Marilee Allen and Geraldine Boylan and Heike Rabe and Ron Portman and Pollyanna Hardy and Sarah Zohar and Klaus Romero and Brian Tseng and Varsha Bhatt-Mehta and Cecil Hahn and Scott Denne and Stephane Auvin and Alexander Vinks and John Lantos and Neil Marlow and Davis, {Jonathan M.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1038/s41390-018-0242-2",
language = "English (US)",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Recommendations for the design of therapeutic trials for neonatal seizures

AU - for the International Neonatal Consortium

AU - Soul, Janet S.

AU - Pressler, Ronit

AU - Allen, Marilee

AU - Boylan, Geraldine

AU - Rabe, Heike

AU - Portman, Ron

AU - Hardy, Pollyanna

AU - Zohar, Sarah

AU - Romero, Klaus

AU - Tseng, Brian

AU - Bhatt-Mehta, Varsha

AU - Hahn, Cecil

AU - Denne, Scott

AU - Auvin, Stephane

AU - Vinks, Alexander

AU - Lantos, John

AU - Marlow, Neil

AU - Davis, Jonathan M.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Although seizures have a higher incidence in neonates than any other age group and are associated with significant mortality and neurodevelopmental disability, treatment is largely guided by physician preference and tradition, due to a lack of data from well-designed clinical trials. There is increasing interest in conducting trials of novel drugs to treat neonatal seizures, but the unique characteristics of this disorder and patient population require special consideration with regard to trial design. The Critical Path Institute formed a global working group of experts and key stakeholders from academia, the pharmaceutical industry, regulatory agencies, neonatal nurse associations, and patient advocacy groups to develop consensus recommendations for design of clinical trials to treat neonatal seizures. The broad expertise and perspectives of this group were invaluable in developing recommendations addressing: (1) use of neonate-specific adaptive trial designs, (2) inclusion/exclusion criteria, (3) stratification and randomization, (4) statistical analysis, (5) safety monitoring, and (6) definitions of important outcomes. The guidelines are based on available literature and expert consensus, pharmacokinetic analyses, ethical considerations, and parental concerns. These recommendations will ultimately facilitate development of a Master Protocol and design of efficient and successful drug trials to improve the treatment and outcome for this highly vulnerable population.

AB - Although seizures have a higher incidence in neonates than any other age group and are associated with significant mortality and neurodevelopmental disability, treatment is largely guided by physician preference and tradition, due to a lack of data from well-designed clinical trials. There is increasing interest in conducting trials of novel drugs to treat neonatal seizures, but the unique characteristics of this disorder and patient population require special consideration with regard to trial design. The Critical Path Institute formed a global working group of experts and key stakeholders from academia, the pharmaceutical industry, regulatory agencies, neonatal nurse associations, and patient advocacy groups to develop consensus recommendations for design of clinical trials to treat neonatal seizures. The broad expertise and perspectives of this group were invaluable in developing recommendations addressing: (1) use of neonate-specific adaptive trial designs, (2) inclusion/exclusion criteria, (3) stratification and randomization, (4) statistical analysis, (5) safety monitoring, and (6) definitions of important outcomes. The guidelines are based on available literature and expert consensus, pharmacokinetic analyses, ethical considerations, and parental concerns. These recommendations will ultimately facilitate development of a Master Protocol and design of efficient and successful drug trials to improve the treatment and outcome for this highly vulnerable population.

UR - http://www.scopus.com/inward/record.url?scp=85061215146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061215146&partnerID=8YFLogxK

U2 - 10.1038/s41390-018-0242-2

DO - 10.1038/s41390-018-0242-2

M3 - Review article

C2 - 30584262

AN - SCOPUS:85061215146

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

ER -